Any feedback?
Literature summary for 6.3.2.12 extracted from
- Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine (2009), PLoS ONE, 4, e6762.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | study on therapeutic efficacy of sulfadoxine-pyrimethamine at two locations in the Peruvian Amazon in order to correlate the presence of polymorphisms in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase to in vitro parasite susceptibility to sulfadoxine and pyrimethamine and to in vivo treatment outcomes. A single mutation present in the isolate obtained at the time of enrollment from either dihydrofolate reductase, 164L, or dihydropteroate synthase, 540E, predicts treatment failure as well as any other single gene alone or in combination. Patients carrying parasites with the dihydrofolate reductase 164L mutation are 3.6times as likely to be treatment failures while patients carrying parasites with the dihydropteroate synthase 540E mutation are 2.6times as likely to fail treatment. Patients with both dihydrofolate reductase 164L and dihydropteroate synthase 540E mutations are 4.1times as likely to be treatment failures compared to patients having both wild forms I164 and K540 | Plasmodium falciparum |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Plasmodium falciparum | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
